Laboratory Monitoring for SIADH
For patients with SIADH, serum sodium should be monitored every 2 hours in severe/symptomatic cases and every 4 hours in mild cases, with daily sodium measurements once stable, along with daily weights, strict intake/output monitoring, and baseline assessment of serum/urine osmolality and urine sodium. 1
Initial Diagnostic Laboratory Panel
When serum sodium falls below 131 mmol/L, obtain the following baseline tests 1:
- Serum sodium and osmolality - to confirm hypotonic hyponatremia
- Urine osmolality (should be >100 mOsm/kg in SIADH)
- Urine sodium (typically >30 mmol/L in SIADH)
- Serum uric acid - levels <4 mg/dL have 73-100% positive predictive value for SIADH 1
- Urine electrolytes including fractional excretion of sodium and urea
Important caveat: Physical examination alone has only 41% sensitivity for determining volume status, so laboratory parameters are essential for distinguishing SIADH from cerebral salt wasting 1. If available, central venous pressure (CVP 6-10 cm H₂O suggests SIADH versus <6 cm H₂O for cerebral salt wasting) provides more reliable volume assessment 1.
Monitoring Frequency During Active Treatment
Severe Symptoms (altered mental status, seizures, Na <120 mmol/L)
- Serum sodium every 2 hours during hypertonic saline administration 1
- Strict intake and output monitoring (hourly)
- Daily weights
- ICU-level care required
Mild Symptoms (nausea, vomiting, headache)
- Serum sodium every 4 hours initially 1
- Daily sodium measurements once stabilized
- Daily weights
- Intermediate care unit monitoring
Asymptomatic or Stable Patients
- Daily serum sodium until levels reach ≥131 mmol/L 1
- Daily weights
- Intake/output monitoring
Critical Safety Parameters
The total sodium correction must not exceed 8 mmol/L over 24 hours to prevent osmotic demyelination syndrome 1. If 6 mmol/L is corrected in the first 6 hours for severe symptoms, increase sodium by no more than 2 mmol/L in the following 18 hours 1.
For chronic hyponatremia, limit correction to <10 mmol/L per day 2, 3. Recent evidence suggests even more conservative targets, with some guidelines recommending not exceeding 10 mmol/L in 24 hours or 18 mmol/L in 48 hours 2.
Additional Monitoring Considerations
When Using Specific Therapies
Hypertonic saline: Requires the most intensive monitoring (every 2 hours) due to risk of overcorrection 1
Fluid restriction: Monitor daily sodium and adjust restriction based on response; approximately 50% of SIADH patients do not respond to fluid restriction alone 3
Vaptans (if used): The first 24 hours are critical - measure sodium at 0,6,24, and 48 hours after initiation 4. Monitor for overly rapid correction, which occurred in 10.2% of patients in registry data 5
Fludrocortisone or hydrocortisone: Monitor serum potassium levels, as hypokalemia requiring correction occurred in patients receiving these agents 1
Long-term Monitoring
Once sodium reaches ≥131 mmol/L and symptoms resolve, transition to less frequent monitoring based on clinical stability. However, 75% of hospitalized SIADH patients are discharged with sodium <135 mmol/L, indicating the need for outpatient follow-up 5.
Common pitfall: ADH levels have limited diagnostic value and should not be routinely measured, as SIADH can occur with undetectable ADH levels 1. Similarly, natriuretic peptides show conflicting results and are not recommended for routine monitoring 1.